期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌新辅助化疗的疗效预测因子 被引量：1

暂未订购
导出
摘要 乳腺癌的新辅助化疗已经成为乳腺癌治疗策略的一部分，并逐渐应用于早期乳腺癌，通过减少肿瘤体积，部分可达到保乳目的，而且理论上可以减少微小转移灶的播散，并观察药物的疗效。
作者 肖宇 李惠平
机构地区 北京大学第三医院肿瘤科
出处 《癌症进展》 2011年第3期302-305,共4页 Oncology Progress
基金 国家自然科学基金(项目编号:30672424)
关键词 乳腺癌 新辅助化疗 预测因子
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Kaufmann M,Hortobagyi GN,Goldhirsch A,et al.Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer:An update[J].J Clin Oncol,2006,24:1940.
  • 2Tewari M,Krishnamurthy A,Shukla HS.Predictive markers of response to neoadjuvant chemotherapy in breast cancer[J].Surg Oncol,2008,17:301.
  • 3肖宇,李惠平,侯宽永,赵红梅,王晶,王墨培,曹宝山.40例乳腺癌新辅助化疗的疗效观察[J].癌症进展,2008,6(2):104-109. 被引量：7
  • 4Rastogi P,Stewart J,Harry D,et al.Preoperative chemotherapy:Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27[J].J Clin Oncol,2008,26:778.
  • 5Bonadonna G,Valagussa P,Zucali R,et al.Primary chemotherapy in surgically resectable breast cancer[J].CA Cancer J Clin,1995,45:227.
  • 6Guarneri V,Broglio K,Kau SW,et al.Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors[J].J Clin Oncol,2006,24:1037.
  • 7Gianni L,Baselga J,Eiermann W,et al.Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide,methotrexate,and fluorouracil and its effects on tumor response as preoperative therapy[J].Clin Cancer Res,2005,11:8715.
  • 8Bear HD,Anderson S,Smith HE,et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J].J Clin Oncol,2006,24 (13):2019.
  • 9MacGrogan G,Mauriac L,Durand M,et al.Primary chemotherapy in breast invasive carcinoma:Predictive value of the immunohistochemical detection of hormonal receptors,p53,c-erbB-2,MiB1,pS2 and GST pi[J].Br J Cancer,1996,74:1458.
  • 10Daidone MG,Veneroni S,Benini E,et al.Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer[J].Int J Cancer,1999,84:580.

二级参考文献17

  • 1李金锋,欧阳涛,王天峰,林本耀.原发性乳腺癌新辅助化疗的临床研究[J].中华肿瘤杂志,2004,26(8):493-495. 被引量：43
  • 2陈灿铭,沈坤炜,柳光宇,吴炅,陆劲松,庄传经,韩企夏,刘邦令,邵志敏,沈镇宙.长春瑞滨和表阿霉素联合新辅助化疗方案治疗局部晚期乳腺癌的临床研究[J].中华外科杂志,2006,44(11):745-747. 被引量：12
  • 3张斌,张强,赵林,龙飞,李爽,姜大庆,徐宏.乳腺癌新辅助化疗疗效的评价及影响因素分析[J].中华肿瘤杂志,2006,28(11):867-870. 被引量：44
  • 4[1]Wolmark N,Wang J,Mamounas E,et al.Preoperative chemotherapy in patients with operable breast cancert Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.J Natl Cancer Inst Monogr,2001,30:96
  • 5[2]Jones RL,Smith IE.Neoadjuvant treatment for earlystage breast cancer:Opportunities to assess tumout response.Lancet Oncol,2006,7:869
  • 6[3]Bear HD,Anderson S,Smith RE,et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Proiect Protocol B-27.J Clin Oncol,2006,24:2019
  • 7[4]Vassilomanolakis M,Koumakis G.,Barbounis V.Firstline chemotherapy with docetaxel and cisplatin in metastatic breast cancer.Breast,2005,14(2):136
  • 8[5]Tulba A,Malik O,Shabana M,et al.Prospective phase Ⅱ study of:neo-adjuvant doxorubicin fohowed sequentially by cisplatin/docetaxel in locally advanced breast cance.Eur J Cancer,2006,4(2):157
  • 9[7]Apple S.K,Suthar F.How do we measure a residual tumor size in Histopathology(the gold standard)after neoadjuvant chemotherapy? Breast,2006,15(3):370
  • 10[8]Ogston KN,Miller ID,Payne S,et al.A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and Survival.Breast,2003,12:320

共引文献22

同被引文献39

  • 1Forouzanfar M H,Foreman K J,Delossantos A M,et al.Breast and cervical cancer in 187 countries between 1980and 2010:asystematic analysis[J].Lancet,2011,378(9801):1461-1484.
  • 2Kaufmann M,yon Minckwitz G,Mamounas EP,et al.Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer[J].Anna&ofsurgical oncology,2012,19(5):1508-1516.
  • 3Keune JD,Jeffe DB,Schootman M,et al.Accuracy of ultrasonography and manmmography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer[J].Am J Surg,2010,199(4):477-484.
  • 4Chagpar AB,Middleton LP,Sahin AA,et al.Accuracy of physica examination ultrasonography,and mammography in predicting residual pathologi tumor size in patients treated with neoadjuvant chemotherapy[J].An Surg,2006,243(2):257-264.
  • 5Bosch AM,Kessels AG,Beets GL,et al.Preoperative estimation of the pathological breast tumour size by physical examination,mammography and ultrasound:a prospective study on 105 invasive tumours[J].Eur J Radiol,2003,48:285-292.
  • 6Corcioni B,Santilli L,Quercia S,et al.Contrast-enhanced US and MRI for assessing the response of breast cancer to neoadjuvant chemotherapy(NAC)[J].J Ultrasound,2008,11:143-150.
  • 7Evans A,Armstrong S,Whelehan P,et al.Can shearwave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer[J].Br J Cancer,2013,109:2798-2802.
  • 8Abdel-Wahab M,Wolfson A,Raub W,et al.The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer:a phase II trial of neoadjuvant MVAC,surgery,and radiation[J].Int J Radiat Oncol Biol Phys,1998,40:875-880.
  • 9Beresford M,Padhani AR,Goh V,et al.Imaging breast cancer response during neoadjuvant systemic therapy[J].Expert Rev Anticancer Ther,2005,5:893-905.
  • 10Hylton N M,Blume J D,Bernreuter W K,et al.Locally advanced breast cancer:MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN6657/I-SPY TRIAL[J].Radiology,2012,263(3):663-672.

引证文献1

癌症进展
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部